Press Releases
May 2024
05.06.2024
05.01.2024
April 2024
04.29.2024
Prescription Medicines Medicines FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
04.29.2024
04.26.2024
Prescription Medicines Medicines U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
04.25.2024
Corporate Finance Pfizer Announces 2024 Shareholder Meeting Preliminary Results
04.24.2024
Corporate Finance Pfizer Declares Second-Quarter 2024 Dividend
04.22.2024
04.11.2024
04.09.2024
March 2024
03.20.2024
03.13.2024
Resource Library
Press Kits
These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.
Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.
For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.
For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".
For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.
Contact Pfizer Media Relations
Media Contacts
United States, Canada, and Latin America
+1 212.733.1226
Europe, Middle East, and Africa
+44-(0)845.300.8033
Asia Pacific
+65.918.732.47
Email
[email protected]